henhaobio
Sign in

Frontiers in Cellular and Infection MicrobiologyMicrobiologyPeer-reviewed journal article

New tools to monitor Pseudomonas aeruginosa infection and biofilms in vivo in C. elegans.

Feng Xue, Martina Ragno, Sarah A. BlackburniD, Michael K. FasseasiD, Sushmita Maitra, Mingzhi LiangiD, Subash Rai, Giulia Mastroianni, Frederique M. Tholozan, Rachel Thompson, Laura E. Sellars, Rebecca A. HalliD, Chris Saunter, David WeinkoveiD, Marina EzcurraiD

PDFDOIPreprint

Abstract

Antimicrobial resistance is a growing health problem. Pseudomonas aeruginosa is a pathogen of major concern because of its multidrug resistance and global threat, especially in health-care settings. The pathogenesis and drug resistance of P. aeruginosa depends on its ability to form biofilms, making infections chronic and untreatable as the biofilm protects against antibiotics and host immunity. A major barrier to developing new antimicrobials is the lack of in vivo biofilm models. Standard microbiological testing is usually performed in vitro using planktonic bacteria, without representation of biofilms, reducing translatability. Here we develop tools to study both infection and biofilm formation by P. aeruginosa in vivo to accelerate development of strategies targeting infection and pathogenic biofilms. Using the nematode Caenorhabditis elegans and P. aeruginosa reporters combined with in vivo imaging we show that fluorescent P. aeruginosa reporters that form biofilms in vitro can be used to visualise tissue infection. Using automated tracking of C. elegans movement, we find that that the timing of this infection corresponds with a decline in health endpoints. In a mutant strain of P. aeruginosa lacking RhlR, a transcription factor that controls quorum sensing and biofilm formation, we find reduced capacity of P. aeruginosa to form biofilms, invade host tissues and negatively impact healthspan and survival. Our findings suggest that RhlR could be a new antimicrobial target to reduce P. aeruginosa biofilms and virulence in vivo and C. elegans could be used to more effectively screen for new drugs to combat antimicrobial resistance.

Citations
5
FWCI
0.58
Field percentile
top 40%

Reproducibility ledger

Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.

Sign in to file a reproducibility report.

Similarity Map
SelectedSame fieldCross-field
THISBernardes '17Kumar '20Sweeney '20Mitsuyama '25Hassan '20Manohar '18
77% semantic matchMicrobiology
Erik van Tilburg Bernardes, Laetitia Charron-Mazenod, David Reading+2 more·Antimicrobial Agents and Chemotherapy·May 1, 2017